Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25
$365.75K+37.7%$265.57K+10.5%$240.4K+2.3%
$6.35M+13.6%$5.59M+49.0%$3.75M+49.0%
$6.72M+14.7%$5.86M+46.7%$3.99M+45.1%
$6.72M+14.7%$5.86M+46.7%$3.99M+45.1%
-$6.72M-14.7%-$5.86M-46.7%-$3.99M-45.1%
$74.1K+150%$29.58K+39.3%$21.24K-6.3%
$2.88M+8.2%$2.66M+1,247%$197.76K+1.4%
$2.63M+2.1%$2.57M
-$380.44K
-$6.72M-14.7%-$5.86M-46.7%-$3.99M-45.1%
-$5.81M-47.3%-$3.94M-45.8%
-$6.72M-14.7%-$5.86M-46.7%-$3.99M-45.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Turn Therapeutics Inc. Common Stock profitable?
Turn Therapeutics Inc. Common Stock is not currently profitable: it reported a net loss of $3.5M over the trailing twelve months.
What is Turn Therapeutics Inc. Common Stock's earnings per share?
Turn Therapeutics Inc. Common Stock's diluted EPS over the trailing twelve months is $-0.13.
Where does Turn Therapeutics Inc. Common Stock's income statement data come from?
Every line is extracted from Turn Therapeutics Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.